|
T-cell/histiocyte rich large B-cell lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Whereas loss of OCT-2 and/or BOB.1 expression had a sensitivity of only 86% and specificity of 100% for CHL versus NLPHL, PMBL, and TCRLBL, lack of both J chain and MEF2B expression was 100% sensitive and 97% specific.
|
28851661 |
2017 |
|
Nodular Lymphocyte Predominant Hodgkin Lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Whereas loss of OCT-2 and/or BOB.1 expression had a sensitivity of only 86% and specificity of 100% for CHL versus NLPHL, PMBL, and TCRLBL, lack of both J chain and MEF2B expression was 100% sensitive and 97% specific.
|
28851661 |
2017 |
|
Multiple Myeloma
|
0.020 |
Biomarker
|
disease |
BEFREE |
When the immunoglobulin-producing myeloma MPC11 is fused to a T lymphoma, Oct-2 production ceases, as does the expression of immunoglobulin, J chain, and several other B cell-specific gene products.
|
7600290 |
1994 |
|
Mediastinal (Thymic) Large B-Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We investigated the utility of J chain and myocyte enhancer factor 2B (MEF2B) in the diagnosis of CHL; NLPHL; PMBL; T-cell/histiocyte-rich large B-cell lymphoma (TCRLBL); and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and CHL, compared with OCT-2 and BOB.1.
|
28851661 |
2017 |
|
Diabetes Mellitus
|
0.110 |
Biomarker
|
group |
BEFREE |
We investigated the influence of diabetes mellitus (DM), glycemic control with insulin, cimetidine (Oct2 inhibitor) and metformin (Oct2 substrate) on the kinetic disposition of GAB in rats.
|
29551575 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.010 |
Biomarker
|
disease |
BEFREE |
We identified Interferon regulating factor 5 (IRF5), solute carrier family 22 member 2 (SLC22A2) and S100 calcium binding protein A12 (S100A12) as the three proteins with the largest fold change between SLE patients and controls (SLE/Control = 1.4, 1.4, and 1.2 respectively).
|
31156624 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We detected nominal evidence of association (P < 0.05) between the SLC22A2 (SNPs rs653753, rs596881, and rs316019) and SLC22A3 (SNPs rs376563, rs2048327, rs2457576, and rs1567438) genes and DN and hypertension in Finnish men with T1DM.
|
20429798 |
2010 |
|
Hypertensive disease
|
0.020 |
GeneticVariation
|
group |
BEFREE |
We detected nominal evidence of association (P < 0.05) between the SLC22A2 (SNPs rs653753, rs596881, and rs316019) and SLC22A3 (SNPs rs376563, rs2048327, rs2457576, and rs1567438) genes and DN and hypertension in Finnish men with T1DM.
|
20429798 |
2010 |
|
Diabetic Nephropathy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We detected nominal evidence of association (P < 0.05) between the SLC22A2 (SNPs rs653753, rs596881, and rs316019) and SLC22A3 (SNPs rs376563, rs2048327, rs2457576, and rs1567438) genes and DN and hypertension in Finnish men with T1DM.
|
20429798 |
2010 |
|
Neoplasms
|
0.050 |
GeneticVariation
|
group |
BEFREE |
We conclude that the expression pattern of OCT2, SSX2-4, and SAGE1 supports the origin of SS from spermatogonia and provides new evidence for heterogeneity of this tumour, potentially linked either to the cellular origin of SS or to partial differentiation during tumour progression, including a hitherto unknown OCT2-positive variant of the tumour likely derived from A(dark) spermatogonia.
|
21706474 |
2011 |
|
Spermatocytic seminoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We conclude that the expression pattern of OCT2, SSX2-4, and SAGE1 supports the origin of SS from spermatogonia and provides new evidence for heterogeneity of this tumour, potentially linked either to the cellular origin of SS or to partial differentiation during tumour progression, including a hitherto unknown OCT2-positive variant of the tumour likely derived from A(dark) spermatogonia.
|
21706474 |
2011 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Using data obtained from the cancer transcriptome database Oncomine and the proteome database The Human Protein Atlas, we identified the repression of organic cation transporter OCT2 as a potential factor contributing to oxaliplatin resistance in RCC.
|
27440728 |
2016 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Using data obtained from the cancer transcriptome database Oncomine and the proteome database The Human Protein Atlas, we identified the repression of organic cation transporter OCT2 as a potential factor contributing to oxaliplatin resistance in RCC.
|
27440728 |
2016 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Using a randomized crossover design and continuous variables such as change in hearing threshold and biomarkers of acute renal injury as short-term endpoints, it was determined that pantoprazole, an organic cation transporter 2 inhibitor, did not ameliorate cisplatin-associated nephrotoxicity or ototoxicity.Cystatin C is a robust method to estimate glomerular filtration rate in patients with cancer.
|
29445029 |
2018 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Using a randomized crossover design and continuous variables such as change in hearing threshold and biomarkers of acute renal injury as short-term endpoints, it was determined that pantoprazole, an organic cation transporter 2 inhibitor, did not ameliorate cisplatin-associated nephrotoxicity or ototoxicity.Cystatin C is a robust method to estimate glomerular filtration rate in patients with cancer.
|
29445029 |
2018 |
|
Glomerular Filtration Rate
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Trans-ethnic kidney function association study reveals putative causal genes and effects on kidney-specific disease aetiologies.
|
30604766 |
2019 |
|
Glomerular Filtration Rate
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Trans-ethnic Fine Mapping Highlights Kidney-Function Genes Linked to Salt Sensitivity.
|
27588450 |
2016 |
|
Machado-Joseph Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
To further investigate the DAT activity in asymptomatic MJD (aMJD) gene carriers, we performed this prospective study using (99m)Tc-TRODAT-1 ([(99m)Tc][2[[2-[[[3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3,2,1]oct-2-yl]-methyl](2-mercaptoethyl)amino]ethyl]amino]ethane-thiolato(3-)-N2,N2',S2,S2]oxo-[1R-(exo-exo)])) brain SPECT on 5 aMJD gene carriers, 10 age-matched MJD patients, and 10 age-matched healthy control subjects.
|
11850478 |
2002 |
|
Hodgkin Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
To check the genomic status of PU.1, BOB1, and OCT2 in HL, we performed metaphase fluorescence in situ hybridization (FISH) analysis of 10 HL cases using locus-specific bacterial artificial chromosome clones.
|
15796964 |
2005 |
|
Adult Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
To check the genomic status of PU.1, BOB1, and OCT2 in HL, we performed metaphase fluorescence in situ hybridization (FISH) analysis of 10 HL cases using locus-specific bacterial artificial chromosome clones.
|
15796964 |
2005 |
|
Childhood Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
To check the genomic status of PU.1, BOB1, and OCT2 in HL, we performed metaphase fluorescence in situ hybridization (FISH) analysis of 10 HL cases using locus-specific bacterial artificial chromosome clones.
|
15796964 |
2005 |
|
Leukemia, Myelocytic, Acute
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
To assess a large series of patients with acute myeloid leukemia (AML) with t(8;21) for both IGH@ and IGK@ B-cell gene rearrangements and for expression of PAX5, OCT2, and Bob.1 by immunohistochemistry and expression of CD19, CD79a, CD20, and CD22 by flow cytometry immunophenotyping.
|
23955454 |
2013 |
|
Cardiac Arrhythmia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Thus elevated concentrations of these drugs as a result of a pharmacokinetic drug-drug interaction via either human multidrug resistance protein 1 or human organic cation transporter 2 (or both) in the renal tubular cells might have caused the arrhythmia in our patient.
|
16580907 |
2006 |
|
Essential Hypertension
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study further suggests a function of OCT2 in blood pressure homeostasis and points to the potential role of the transporter in the development of essential hypertension.
|
17060063 |
2006 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that in addition to modified oral absorption of certain drugs, it is possible that the renal excretion of drugs that are multidrug resistance-associated protein 2, organic anion transporter 3, and organic cation transporter 2 substrates could be altered in AD.
|
30825461 |
2019 |